Healthcare shares are flat in pre-market, while
Biopharmaceutical company Amarin Corporation plc (
) said that the number of patients enrolled in its REDUCE-IT
cardiovascular outcomes study of Vascepa (icosapent ethyl) capsules
has surpassed 6,000.
The REDUCE-IT study will evaluate the effectiveness and safety
of Vascepa (icosapent ethyl) capsules, as an adjunct to optimized
statin therapy, in reducing the incidence of first major
cardiovascular events in a patient population at high risk for such
AMRN edged up by $0.02 to $6.42 in pre-market trade.
And, Ophthotech (
) said it has priced its initial public offering of 7.6 million
shares at $22.00 per share. Underwriters have a 30-day option to
buy an additional 1.14 million shares. Ophthotech will start
trading on the Nasdaq Global Select Market today under the ticker
Finally, Syngeva BioPharma (
) said it has priced a 2.75 million public share sale at $56.63 per
share, in line with yesterday's closing price.
Underwriters have the option to buy an additional 412,500
GEVA added 0.25% to $56.77 in after-hours trade yesterday. The
stock is trading at the top end of its 52-week range between $38.58
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.